drugset / Trial / NCT03692221

Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease

NCT03692221

RandomizedParallel-groupOpen-labelTreatment

Summary

This study seeks to bridge these technologies and obtain data regarding the safety and efficacy of image guided percutaneous needle injection of expanded autologous bone marrow derived mesenchymal stem cells to symptomatic degenerated intervertebral discs in humans. The primary outcome will be to assess the safety and efficacy and monitor for adverse events.

Timeline

Start
2019-06
Primary completion
2021-09-30
Completion
2022-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 unknown Other
Subject mesenchymal stem cells Cell therapy 4e+06 unknown Other